SC 13G: ORAMED PHARMACEUTICALS INC.
Ticker: ORMP · Form: SC 13G · Filed: Sep 16, 2024 · CIK: 1176309
| Field | Detail |
|---|---|
| Company | Oramed Pharmaceuticals Inc. (ORMP) |
| Form Type | SC 13G |
| Filed Date | Sep 16, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.012 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sc-13g
AI Summary
SC 13G filing by ORAMED PHARMACEUTICALS INC..
Risk Assessment
Risk Level: low
FAQ
What type of filing is this?
This is a SC 13G filing submitted by Oramed Pharmaceuticals Inc. (ticker: ORMP) to the SEC on Sep 16, 2024.
What is the risk level of this SC 13G filing?
This filing has been assessed as low risk.
What are the key financial figures in this filing?
Key dollar amounts include: $0.012 (Name of Issuer) Common Stock par value $0.012 per share (Title of Class of Securiti).
How long is this filing?
Oramed Pharmaceuticals Inc.'s SC 13G filing is 3 pages with approximately 947 words. Estimated reading time is 4 minutes.
Where can I view the full SC 13G filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 947 words · 4 min read · ~3 pages · Grade level 8 · Accepted 2024-09-16 16:42:03
Key Financial Figures
- $0.012 — Name of Issuer) Common Stock par value $0.012 per share (Title of Class of Securiti
Filing Documents
- ormp13g.htm (SC 13G) — 53KB
- 0001373604-24-000092.txt ( ) — 55KB
(a)
Item 1(a). Name of Issuer: Oramed Pharmaceuticals Inc.
(b)
Item 1(b). Address of Issuer's Principal Executive Offices: 1185 Avenue of the Americas, Third Floor, New York, NY
(a)
Item 2(a). Name of Person Filing: BML Investment Partners, L.P
(b)
Item 2(b). Address of Principal Business Office or, if none, Residence: 65 E Cedar, Suite 2 Zionsville, IN 46077
(c)
Item 2(c). Citizenship: Delaware
(d)
Item 2(d). Title of Class of Securities: Common Stock
(e)
Item 2(e). CUSIP Number: 68403P203 Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing Is a(n): (a) Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o); (b) Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c); (c) Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c); (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E); (f) Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F); (g) Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (h) Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J); (k) Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ . Item 4. (a) Amount beneficially owned: 2,048,634 (b) Percent of class: 5.0 (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote:0 (ii) Shared power to vote or to direct the vote: 2,048,634 (iii) Sole power to dispose or to direct the disposition of:0 (iv) Shared power to dispose or to direct the disposition of: 2,048,634 Item 5. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class